



21 July 2016  
EMA/487528/2016  
Human Medicines Evaluation Division

## Overview of (invented) names reviewed in July 2016 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 18-21 July 2016

	NRG meeting		NRG meeting		NRG meeting		NRG meeting		NRG meeting		NRG meeting		2016	
	03 Feb 2016		06 April 2016		01 June 2016		06 Jul 2016		21 Sep 2016		23 Nov 2016			
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names	27	35	48	52	40	42	19	27						
Justification for retention of (invented) name *	0	4	1	6	1	1	7	3						

\*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.



	NRG meeting 03 Feb 2016		NRG meeting 06 April 2016		NRG meeting 01 June 2016		NRG meeting 06 Jul 2016		NRG meeting 21 Sep 2016		NRG meeting 23 Nov 2016		2016	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	72	39	113	90	110	77	61	55						
<b>Criterion - Safety concerns</b>														
Similarity with other (invented) name	62	33	108	86	96	71	52	47						
Conveys misleading therapeutic/pharmaceutical connotations	0	0	0	0	1	0	1	0						
Misleading with respect to composition	1	0	1	0	0	0	2	0						
<b>Criterion - INN concerns</b>														
Similarity with INN	3	3	2	3	4	2	1	3						
Inclusion of INN stem	0	0	0	1	1	0	0	2						
<b>Criterion - Other public health concerns</b>														
Unacceptable qualifiers	1	0	0	0	2	0	0	0						
Conveys a promotional message	1	0	1	0	1	3	2	1						
Appears offensive or has an inappropriate connotation	1	0	0	0	2	1	1	1						
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0	0	0	0	0						
Similarity between name of prodrug and related active substance	0	0	0	0	0	0	0	0						
Others	3	3	1	0	3	0	2	1						

See *Guideline on the [Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#)* for detailed explanations of criteria used.